MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

NCT05286957 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: adjuvant tislelizumab and chemotherapy for MRD+ patients
DRUG: adjuvant tislelizumab and chemotherapy for MRD+ patients
DRUG: adjuvant chemotherapy for MRD- patients

Sponsor

The First Affiliated Hospital of Zhengzhou University

Collaborators

[object Object]